MX2024003475A - Polimorfos como inhibidores de erbb. - Google Patents

Polimorfos como inhibidores de erbb.

Info

Publication number
MX2024003475A
MX2024003475A MX2024003475A MX2024003475A MX2024003475A MX 2024003475 A MX2024003475 A MX 2024003475A MX 2024003475 A MX2024003475 A MX 2024003475A MX 2024003475 A MX2024003475 A MX 2024003475A MX 2024003475 A MX2024003475 A MX 2024003475A
Authority
MX
Mexico
Prior art keywords
polymorphs
erbb inhibitors
morphic forms
present disclosure
morphic
Prior art date
Application number
MX2024003475A
Other languages
English (en)
Spanish (es)
Inventor
Siyi Jiang
Wu- Yan ZHANG
Reza Foroughi
Meiqi Li
Juanjuan Shi
Original Assignee
Black Diamond Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black Diamond Therapeutics Inc filed Critical Black Diamond Therapeutics Inc
Publication of MX2024003475A publication Critical patent/MX2024003475A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024003475A 2021-09-21 2022-09-21 Polimorfos como inhibidores de erbb. MX2024003475A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163246451P 2021-09-21 2021-09-21
PCT/US2022/044232 WO2023049168A1 (en) 2021-09-21 2022-09-21 Polymorphs as erbb inhibitors

Publications (1)

Publication Number Publication Date
MX2024003475A true MX2024003475A (es) 2024-04-05

Family

ID=83691602

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003475A MX2024003475A (es) 2021-09-21 2022-09-21 Polimorfos como inhibidores de erbb.

Country Status (10)

Country Link
US (1) US20240425492A1 (cg-RX-API-DMAC10.html)
EP (1) EP4405350A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024534517A (cg-RX-API-DMAC10.html)
KR (1) KR20240099193A9 (cg-RX-API-DMAC10.html)
CN (1) CN119110799A (cg-RX-API-DMAC10.html)
AU (1) AU2022352658A1 (cg-RX-API-DMAC10.html)
CA (1) CA3231697A1 (cg-RX-API-DMAC10.html)
IL (1) IL311354A (cg-RX-API-DMAC10.html)
MX (1) MX2024003475A (cg-RX-API-DMAC10.html)
WO (1) WO2023049168A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598B2 (en) 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
WO2024179451A1 (zh) * 2023-03-02 2024-09-06 江苏康缘药业股份有限公司 一种炔基取代的喹唑啉化合物的晶型、其制备方法和应用
WO2025038731A1 (en) * 2023-08-15 2025-02-20 Black Diamond Therapeutics, Inc. Method of treating cancers with alkyne substituted quinazoline derivatives
CN122580302A (zh) * 2023-12-21 2026-08-14 黑钻治疗公司 Erbb抑制剂的固体形式
WO2025137421A1 (en) * 2023-12-21 2025-06-26 Black Diamond Therapeutics, Inc. Compositions comprising alkyne substituted quinazoline derivatives and related uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598B2 (en) * 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
MX2023004998A (es) * 2020-11-02 2023-05-12 Black Diamond Therapeutics Inc Metodo para tratar canceres con derivados de quinazolina sustituida con alquino.

Also Published As

Publication number Publication date
IL311354A (en) 2024-05-01
EP4405350A1 (en) 2024-07-31
KR20240099193A9 (ko) 2025-12-10
KR20240099193A (ko) 2024-06-28
CN119110799A (zh) 2024-12-10
CA3231697A1 (en) 2023-03-30
AU2022352658A1 (en) 2024-03-21
JP2024534517A (ja) 2024-09-20
US20240425492A1 (en) 2024-12-26
WO2023049168A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
CR20220354A (es) Inhibidores de egfr
MX2023010411A (es) Inhibidores de erbb/btk.
MX2025002170A (es) Inhibidores de kras g12c
ZA202110422B (en) Heterocyclic compounds, preparation methods and uses thereof
MX2024001893A (es) Compuestos heterociclicos y metodos de uso.
MX2023000333A (es) Sales y formas de un inhibidor wee1.
MX2023012726A (es) Compuestos heterociclicos y metodos de uso.
MX2026003002A (es) Inhibidores de kras
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
MX2023008954A (es) Inhibidores de los receptores erbb.
MX2025001648A (es) Inhibidores del oncogen homologo del virus de sarcoma de rata kirsten (kras)
MX2025015502A (es) Inhibidores del oncogén de sarcoma de rata de kirsten (kras)
MX2024000230A (es) Inhibidores de cdk2.
MX2020010181A (es) Compuestos de piperidina como inhibidores covalentes de menina.
GEP20115304B (en) PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.
PT1934174E (pt) Azetidinas como inibidores de mek para o tratamento de doenças proliferativas
CR20240014A (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
MX2025001982A (es) Inhibidores de kif18a y usos de estos
SA521420951B1 (ar) مركبات ترايازول تعمل كمثبطات للجليكولات أوكسيداز
MX2024013095A (es) Compuestos inhibidores de fgfr2
ZA202006071B (en) Antiproliferation compounds and uses thereof
MX2024008868A (es) Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
MX2023001275A (es) Inhibidores de raf biciclicos fusionados y metodos para su uso.
MX2025012153A (es) Inhibidores de cdk2